MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
BLUE - Bluebird bio Inc
$29.82
0.32(1.08%)7:59:56 PM 5/12/2021
bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - approved drug is betibeglogene autotemcel , which treats transfusion-dependent beta thalassemia , a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap2B
PE Ratio-3.1
PEG Ratio0.1
P/B1.5
P/S (ttm)8.2
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %14%
Held by Institutions %84%
1 Day Vol Adjusted Return0.3
1 Month Vol Adjusted Return1.9
3 Month Vol Adjusted Return-6.0
6 Month Vol Adjusted Return-6.0
20 Days SMA Price ZScore0.6
50 Days SMA Price ZScore0.0
12 -26 Days PPO-0.4
1 Month Average Short Volume Ratio47.9
1 Day Volume Change ZScore0.1
1 Month Daily Vol2.7
Related Topics
leak data
Peers

Stock news

    05/5/2021BLUE
    Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of -0.66% and 19.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    05/5/2021BLUE
    bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress

    bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.

    05/3/2021BLUE
    Checking In on 3 Stock Samplers

    In this episode of Rule Breaker Investing, we review 5 Stocks for the Coronavirus, 5 Stocks for the Age of Miracles, and 5 Stocks I Own That You Should, Too. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. David Gardner: Last April, the market was in as dark a place as any of us have seen for more than 10 years -- the 35% loss of the S&P 500 in 32 days.

    05/3/2021BLUE
    Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    05/3/2021BLUE
    bluebird bio Announces May Investor Events

    bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

    05/1/2021BLUE
    What Investors Need to Know About This $419,500 CAR-T Cancer Treatment

    Bristol Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) recently gained Food and Drug Administration approval of Abecma. In this video from Motley Fool Live, recorded on March 29, Fool.com Contributors Brian Orelli and Keith Speights discuss the prospects for Abecma and what the companies are doing to increase the potential market for the chimeric antigen receptor T-cell (CAR-T) product. Brian Orelli: On Friday, the FDA approved Bristol Myers Squibb and Bluebird Bio's CAR-T treatment ...

    05/1/2021BLUE
    Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock?

    Last week, Vertex Pharmaceuticals (NASDAQ: VRTX) announced that it would pay CRISPR Therapeutics (NASDAQ: CRSP) a whopping $900 million to take more control of the duo's gene therapy collaboration, CTX001. CTX001 is being investigated as a potentially curative treatment for severe sickle cell disease and beta thalassemia, a rare blood disorder. Beti-cel is already on the market in the EU for beta thalassemia, but Bluebird is still facing a slew of problems in the U.S. and in major European mar...

    04/22/2021BLUE
    Is BLUE Stock A Buy or Sell?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

    04/21/2021BLUE
    Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.